Taysha Gene Therapies, Inc. TSHA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $7.47M-23.6% | $9.77M+54.9% | $6.31M-22.1% | $8.1M+12.1% | $7.22M-13.3% | ||
| $104.65M+21.1% | $86.4M+12.5% | $76.78M+16.4% | $65.98M+8.3% | $60.91M-7.7% | ||
| $35.39M+4.5% | $33.87M+7.0% | $31.66M+1.2% | $31.29M+4.2% | $30.03M+3.7% | ||
| —— | —— | —— | —— | —— | ||
| $140.03M+16.4% | $120.27M+10.9% | $108.44M+6.2% | $102.1M+6.6% | $95.77M-4.0% | ||
| $140.03M+16.4% | $120.27M+10.9% | $108.44M+6.2% | $102.1M+6.6% | $95.77M-4.0% | ||
| -$132.56M-20.0% | -$110.5M-8.2% | -$102.13M-8.6% | -$94M-6.2% | -$88.55M+3.2% | ||
| -1,774.4%-644pp | -1,130.6%+488pp | -1,618.5%-458pp | -1,160.8%+64.9pp | -1,225.8%-128pp | ||
| $53K-15.9% | $63K-13.7% | $73K-11.0% | $82K-10.9% | $92K-9.8% | ||
| $10.48M+13.7% | $9.22M+14.5% | $8.05M+15.2% | $6.99M+6.4% | $6.57M-5.3% | ||
| $2.69M+78.8% | $1.5M-31.7% | $2.2M+71.4% | $1.28M-28.0% | $1.78M-17.4% | ||
| —— | —— | —— | —— | —— | ||
| -$129.88M-19.2% | -$109M-9.1% | -$99.93M-7.8% | -$92.72M-6.9% | -$86.77M+2.8% | ||
| -1,738.4%-623pp | -1,115.3%+468pp | -1,583.7%-439pp | -1,145%+56.1pp | -1,201.1%-129pp | ||
| -$0.38-11.8% | -$0.34-3.0% | -$0.33+2.9% | -$0.340.0% | -$0.34+5.6% | ||
| -$0.38-11.8% | -$0.34-3.0% | -$0.33+2.9% | -$0.340.0% | -$0.34+5.6% | ||
| 1.3B+7.8% | 1.2B+5.9% | 1.2B+7.9% | 1.1B+6.4% | 1B+3.9% | ||
| 1.3B+7.8% | 1.2B+5.9% | 1.2B+7.9% | 1.1B+6.4% | 1B+3.9% | ||
| $6.11M-1.0% | $6.17M+21.6% | $5.07M-3.2% | $5.24M+3.6% | $5.06M+10.4% | ||
| $1.3M+8.5% | $1.2M+216% | $380K+2,823% | $13K+103% | -$455K-2,744% | ||
| -$335K-15.1% | -$291K+11.0% | -$327K+11.9% | -$371K-303% | -$92K+16.4% | ||
| -$132.56M-20.0% | -$110.5M-8.2% | -$102.13M-8.6% | -$94M-6.2% | -$88.55M+3.2% | ||
| -$131.47M-20.2% | -$109.42M-8.3% | -$101.04M-8.9% | -$92.82M-6.2% | -$87.36M+3.2% | ||
| -$131.47M-20.2% | -$109.42M-8.3% | -$101.04M-8.9% | -$92.82M-6.2% | -$87.36M+3.2% | ||
| -1,759.7%-640pp | -1,119.6%+482pp | -1,601.3%-455pp | -1,146.2%+63.2pp | -1,209.3%-127pp | ||
| -$132.56M-20.0% | -$110.5M-8.2% | -$102.13M-8.6% | -$94M-6.2% | -$88.55M+3.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Taysha Gene Therapies, Inc.'s revenue?
- Taysha Gene Therapies, Inc. (TSHA) generated $7.5M in revenue over the trailing twelve months, up 3.4% year over year.
- Is Taysha Gene Therapies, Inc. profitable?
- Taysha Gene Therapies, Inc. is not currently profitable: it reported a net loss of $129.9M over the trailing twelve months, a -1738.4% net margin.
- What is Taysha Gene Therapies, Inc.'s earnings per share?
- Taysha Gene Therapies, Inc.'s diluted EPS over the trailing twelve months is $-0.38.
- Where does Taysha Gene Therapies, Inc.'s income statement data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
